Document is current
Any future updates will be listed below
-
Authors
Breisnes, Helene Wallem
Simões, Filipa Bica
Frederiksen, Peder
Nielsen, Signe Holm
Leeming, Diana Julie
Cahn, Tony
O’Shea, Ciara
Hove, Kai
Layton, Mark
Karsdal, Morten Asser
Bay-Jensen, Anne-Christine
Sand, Jannie Marie Bülow
Mukherjee, Sumanta
-
Funding
Funding for this research was provided by:
Danish Research Foundation
GSK (Study 214094)
- License Information
-
More Information
Article History
Received: 25 March 2026
Accepted: 16 June 2026
First Online: 25 June 2026
Declarations
:
: This post-hoc analysis was covered by the original ethics approval and informed consent of the OSCAR study. The OSCAR study was conducted in accordance with the Declaration of Helsinki, Council for International Organisations of Medical Sciences International Ethical Guidelines, International Conference on Harmonisation, Good Clinical Practice, and applicable country-specific regulatory requirements. Before enrolment, informed consent was obtained from the patient or their legally authorised representative. According to the qualified vendor BioIVT, healthy samples were collected in accordance with applicable laws, regulations and ordinances. All informed consent form templates were subject to review and approved by Ethics Committees.
: F.B Simões, P. Frederiksen, S. Holm Nielsen, D. J. Leeming, M. A. Karsdal, (A) C. Bay-Jensen, and J. M. (B) Sand are employees and may be shareholders of Nordic Bioscience, a company involved in the discovery and development of biomarkers. H. W. Breisnes is a PhD student at the University of Copenhagen conducting her project in collaboration with Nordic Bioscience. T. Cahn, (C) O’Shea, K. Hove, M. Layton, and S. Mukherjee are employees and may be shareholders of GSK.
